Quick Answer
Q32 Bio Inc. reported Cash And Cash Equivalents At Carrying Value of $48.30 million for the year ending 2025.
- Q32 Bio Inc. showed a decrease of -38.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Q32 Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $26.50 million | Q2 2017: $20.43 million | Q3 2017: $97.77 million | Q1 2018: $46.21 million | Q2 2018: $94.96 million | Q3 2018: $36.04 million | Q1 2019: $40.84 million | Q2 2019: $115.57 million | Q3 2019: $77.56 million | Q1 2020: $143.37 million | Q2 2020: $167.64 million | Q3 2020: $178.00 million | Q1 2021: $104.42 million | Q2 2021: $116.31 million | Q3 2021: $95.83 million | Q1 2022: $248.13 million | Q2 2022: $176.19 million | Q3 2022: $43.16 million | Q1 2023: $31.41 million | Q2 2023: $20.06 million | Q3 2023: $36.26 million | Q1 2024: $115.51 million | Q2 2024: $97.66 million | Q3 2024: $89.08 million | Q1 2025: $65.48 million | Q2 2025: $54.83 million | Q3 2025: $49.04 million.
- Over the full 10 years of available data (2016 to 2025), Q32 Bio Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 324.0%.
- Historical annual values: Fiscal year 2025: $48.30 million | Fiscal year 2024: $77.97 million | Fiscal year 2023: $25.62 million | Fiscal year 2022: $33.99 million | Fiscal year 2021: $108.38 million | Fiscal year 2020: $217.43 million | Fiscal year 2019: $53.77 million | Fiscal year 2018: $38.22 million | Fiscal year 2017: $51.58 million | Fiscal year 2016: $11.39 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: